InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Rodino-Klapac Louise, Directeur Scientifique. Officer active across 1 companies, notably Sarepta Therapeutics, Inc.. Cumulatively, 6 reports have been published. Total volume traded: €533k. The latest transaction was disclosed on 4 March 2022 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations6 total
€87,0231,216 shares@ €71.56510.0039% mcap13.2% of flow
Common Stock
SEC:0001209191-22-017343:0·
€38,275572 shares@ €66.91380.0017% mcap5.8% of flow
Common Stock
SEC:0001209191-22-014409:0·
€266,6693,780 shares@ €70.5474100.0% of flow
Common Stock
SEC:0001209191-21-066948·
Ideal exit: 21 Aug 2022 (T+270)
€266,6693,780 shares@ €70.54740.012% mcap40.5% of flow
Common Stock
SEC:0001209191-21-066948:0·
Ideal exit: 21 Aug 2022 (T+270)
040,000 shares0
Common Stock
SEC:0001209191-21-065314·
040,000 shares0
Common Stock
SEC:0001209191-21-065314:0·
6 of 6 declarations
About Rodino-Klapac Louise
Louise Rodino-Klapac is the Chief Scientific Officer and Head of R&D at Sarepta Therapeutics, Inc. She oversees the company's research and development activities, playing a key role in innovation and the development of new products. Her scientific expertise is essential to the company's mission.
